Misplaced Pages

Alsactide: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editNext edit →Content deleted Content addedVisualWikitext
Revision as of 03:26, 21 June 2020 editDMacks (talk | contribs)Edit filter managers, Autopatrolled, Administrators186,553 edits Remove malformatted |molecular_weight= when infobox can autocalculate it, per Misplaced Pages talk:WikiProject Pharmacology#Molecular weights in drugboxes (via WP:JWB)← Previous edit Revision as of 05:12, 14 October 2020 edit undoBoghog (talk | contribs)Autopatrolled, Extended confirmed users, IP block exemptions, New page reviewers, Pending changes reviewers, Rollbackers, Template editors137,805 edits tweak citesNext edit →
Line 45: Line 45:
}} }}


'''Alsactide''' (]) (brand name '''Synchrodyn 1-17''' or simply '''Synchrodyn''', former development code name '''Hoechst 433'''), also known as '''alisactide''', is a ] ] and ] of ] (ACTH) which is used in ] as a ] ] in ] function for ].<ref name="Elks2014">{{cite book|author=J. Elks|title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies|url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA34|date=14 November 2014|publisher=Springer|isbn=978-1-4757-2085-3|pages=34–}}</ref><ref>{{cite book|title=Index Nominum 2000: International Drug Directory|url=https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA33|date=January 2000|publisher=Taylor & Francis|isbn=978-3-88763-075-1|pages=33–}}</ref><ref name="MortonHall2012">{{cite book|author1=I.K. Morton|author2=Judith M. Hall|title=Concise Dictionary of Pharmacological Agents: Properties and Synonyms|url=https://books.google.com/books?id=tsjrCAAAQBAJ&pg=PA12|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-94-011-4439-1|pages=12–}}</ref> Like ACTH, alsactide is thought to act as a non-selective ] of the ]s, including the ] (MC<sub>2</sub>R).{{Citation needed|date=May 2015}} However, it appears to show a different profile of ] ] relative to ACTH, as it apparently demonstrated no evidence of inhibition of ] ACTH in ] patients.<ref name="Kontogeorgos2004">{{cite book|author=George Kontogeorgos|title=Molecular Pathology of the Pituitary|url=https://books.google.com/books?id=Atvixzf-d5wC&pg=PA66|date=1 January 2004|publisher=Karger Medical and Scientific Publishers|isbn=978-3-8055-7740-3|pages=66–}}</ref> '''Alsactide''' (]) (brand name '''Synchrodyn 1-17''' or simply '''Synchrodyn''', former development code name '''Hoechst 433'''), also known as '''alisactide''', is a ] ] and ] of ] (ACTH) which is used in ] as a ] ] in ] function for ].<ref name="Elks2014">{{cite book | vauthors = Elks J |title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies|url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA34|date=14 November 2014|publisher=Springer|isbn=978-1-4757-2085-3|pages=34–}}</ref><ref>{{cite book|title=Index Nominum 2000: International Drug Directory|url=https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA33|date=January 2000|publisher=Taylor & Francis|isbn=978-3-88763-075-1|pages=33–}}</ref><ref name="MortonHall2012">{{cite book| vauthors = Morton IK, Hall JM |title=Concise Dictionary of Pharmacological Agents: Properties and Synonyms|url=https://books.google.com/books?id=tsjrCAAAQBAJ&pg=PA12|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-94-011-4439-1|pages=12–}}</ref> Like ACTH, alsactide is thought to act as a non-selective ] of the ]s, including the ] (MC<sub>2</sub>R).{{Citation needed|date=May 2015}} However, it appears to show a different profile of ] ] relative to ACTH, as it apparently demonstrated no evidence of inhibition of ] ACTH in ] patients.<ref name="Kontogeorgos2004">{{cite book | vauthors = Kontogeorgos G |title=Molecular Pathology of the Pituitary|url=https://books.google.com/books?id=Atvixzf-d5wC&pg=PA66|date=1 January 2004|publisher=Karger Medical and Scientific Publishers|isbn=978-3-8055-7740-3|pages=66–}}</ref>


==See also== ==See also==

Revision as of 05:12, 14 October 2020

Pharmaceutical compound
Alsactide
Clinical data
ATC code
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
ECHA InfoCard100.047.442 Edit this at Wikidata
Chemical and physical data
FormulaC99H155N29O21S
Molar mass2119.57 g·mol
3D model (JSmol)
SMILES
  • /N=C(\N)/NCCC(C(=O)N(Cc1cc2c1cccc2)C(=O)NCC(=O)N(CCCCN)C(=O)N3CCC3C(=O)N(C(C)C)C(=O)NCC(=O)N(CCCCN)C(=O)N(CCCCN)C(=O)N(CCCCN)C(=O)NCCCCN)NC(=O)(Cc4ccccc4)NC(=O)(Cc5cnc5)NC(=O)(CCC(=O)O)NC(=O)(CCSC)NC(=O)(CO)NC(=O)(Cc6ccc(cc6)O)NC(=O)CCN
InChI
  • InChI=1S/C99H155N29O21S/c1-59(2)84(97(148)113-56-81(132)115-68(26-10-14-40-101)87(138)119-69(27-11-15-41-102)88(139)118-67(25-9-13-39-100)85(136)109-45-18-17-43-104)127-96(147)79-30-20-47-128(79)98(149)73(28-12-16-42-103)116-82(133)55-112-86(137)76(51-62-53-111-66-24-8-7-23-65(62)66)124-89(140)70(29-19-46-110-99(106)107)120-93(144)75(49-60-21-5-4-6-22-60)123-94(145)77(52-63-54-108-58-114-63)125-90(141)71(35-36-83(134)135)121-91(142)72(38-48-150-3)122-95(146)78(57-129)126-92(143)74(117-80(131)37-44-105)50-61-31-33-64(130)34-32-61/h4-8,21-24,31-34,53-54,58-59,67-79,84,111,129-130H,9-20,25-30,35-52,55-57,100-105H2,1-3H3,(H,108,114)(H,109,136)(H,112,137)(H,113,148)(H,115,132)(H,116,133)(H,117,131)(H,118,139)(H,119,138)(H,120,144)(H,121,142)(H,122,146)(H,123,145)(H,124,140)(H,125,141)(H,126,143)(H,127,147)(H,134,135)(H4,106,107,110)/t67-,68-,69-,70-,71-,72-,73-,74-,75-,76-,77-,78-,79-,84-/m0/s1
  • Key:DIDCGVRALANKIU-OTEFFYEFSA-N
  (verify)

Alsactide (INN) (brand name Synchrodyn 1-17 or simply Synchrodyn, former development code name Hoechst 433), also known as alisactide, is a synthetic peptide and analogue of adrenocorticotropic hormone (ACTH) which is used in Italy as a diagnostic agent in kidney function for adrenal insufficiency. Like ACTH, alsactide is thought to act as a non-selective agonist of the melanocortin receptors, including the ACTH receptor (MC2R). However, it appears to show a different profile of receptor selectivity relative to ACTH, as it apparently demonstrated no evidence of inhibition of endogenous ACTH in Addison's disease patients.

See also

References

  1. Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 34–. ISBN 978-1-4757-2085-3.
  2. Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 33–. ISBN 978-3-88763-075-1.
  3. Morton IK, Hall JM (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 12–. ISBN 978-94-011-4439-1.
  4. Kontogeorgos G (1 January 2004). Molecular Pathology of the Pituitary. Karger Medical and Scientific Publishers. pp. 66–. ISBN 978-3-8055-7740-3.
Diagnostic agents (V04)
Digestive system
Diabetes
Fat absorption
Bile duct patency
Liver functional capacity
Gastric secretion
Exocrine pancreatic function
Endocrine system
Pituitary function
Thyroid function
Fertility disturbances
Tuberculosis
Renal function
Melanocortin receptor modulators
MC1
MC2
MC3
MC4
MC5
Unsorted
Others
Categories: